Outlook Therapeutics (OTLK) Shares Performance
- Last 24‑hour movement: Up 7.88 % to USD 0.56.
- Current market price: USD 0.56 per share.
- Shares outstanding: 243.4 million.
- Market capitalization: USD 126.6 million.
- Volume traded in last 24 hours: USD 1.7 million.
- Performance since end of last month: Down 19.4 %.
- 200‑day simple moving average: USD 0.66.
- 52‑week high: USD 2.54 (17 Dec 2025).
- 52‑week low: USD 0.16 (24 Mar 2026).
Related Stock Movements (Past 24 hours)
| Ticker | Movement | Current Price (USD) | Market Cap (USD million) | Notes |
|---|---|---|---|---|
| CEPS | +0.3 % | 10.15 | 149 | Price‑to‑earnings ratio 22.83 |
| OSS | +1.98 % | 6.18 | 151.1 | Ocean Sciences Ltd reports first commercial sale of Eucheuma spinosum seaweed to a Chinese buyer; shipment of 25 metric tonnes arriving at Xiamen Port. Expansion into iota‑carrageenan market. |
| VNCE | +0.77 % | 11.76 | 151.1 | Price/earnings ratio 20.31 |
| TARA | –2.34 % | 2.50 | 151.3 | |
| STIM | +1.52 % | 2.01 | 150.9 | Announces release of Q3 2026 financial results on 4 Nov 2026; conference call scheduled for the same day. Provides non‑drug, non‑invasive treatments for major depressive disorder and other neuro‑health conditions. |
Company Overview – Outlook Therapeutics, Inc.
- Industry: Biotechnology, Health Care.
- Sector: Clinical‑stage biopharmaceuticals.
- Primary Focus: Development and commercialization of complex biosimilar therapeutics, especially monoclonal antibodies for immunology and oncology indications.
- Headquarters: Iselin, United States.
- Public Listing: Nasdaq; IPO on 13 May 2016.
The company continues to pursue its strategy of identifying and advancing biosimilar candidates, leveraging its platform capabilities to address unmet needs in immunology and oncology.
